home / stock / rain / rain news

RAIN News and Press, Rain Therapeutics Inc. From 12/29/22

Stock Information
Company Name: Rain Therapeutics Inc.
Stock Symbol: RAIN
Market: NASDAQ
Website: rainthera.com
Menu
RAIN RAIN Quote RAIN Short RAIN News RAIN Articles RAIN Message Board
Get RAIN Alerts

News, Short Squeeze, Breakout and More Instantly...
RAIN - Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 com...
RAIN - Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference

NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex th...

RAIN - Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactiv...

RAIN - Rain Therapeutics to Participate in Piper Sandler's 34th Annual Healthcare Conference

NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 comp...
RAIN - Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactiv...

RAIN - Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 compl...

RAIN - Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript

Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Robert Doebele – Chief Scientific Officer Richard Bry...
RAIN - Rain Therapeutics GAAP EPS of -$0.68 in-line

Rain Therapeutics press release ( NASDAQ: RAIN ): Q3 GAAP EPS of -$0.68 in-line. End of third quarter cash balance of $90.7 million excludes the $50.0 million registered offering For further details see: Rain Therapeutics GAAP EPS of -$0.68 in-line

RAIN - Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – &...

RAIN - Rain Therapeutics prices $50M stock offering

Rain Therapeutics ( NASDAQ: RAIN ) priced a registered offering to raise ~$50M in gross proceeds. The company is offering ~6.86M common shares and ~1.72M shares of non-voting common stock, at $5.83 per share. Rain added that the shares of non-voting common stock ar...
Previous 10 Next 10